Regeneron jumps as buyback authorization and recent FDA wins keep bid under shares
Regeneron shares rose about 3% as investors continued to reprice the company after its late-April Q1 2026 report highlighted 19% revenue growth and a newly authorized $3 billion share repurchase program. The move also reflects renewed focus on recent FDA milestones, including approval of Otarmeni for genetic hearing loss and expanded EYLEA HD dosing durability.
1) What’s moving REGN today
Regeneron Pharmaceuticals (REGN) is trading higher in the U.S. session Wednesday, May 6, 2026, with the stock up roughly 3% to about $725.52. The move appears driven by continued post-earnings repositioning after the company’s late-April Q1 2026 update, where management emphasized strong top-line growth alongside a major incremental capital-return lever: a new authorization to repurchase up to $3 billion of common stock. (investor.regeneron.com)
2) The fundamental backdrop investors are leaning on
In its Q1 2026 results and operating update, Regeneron highlighted 19% total revenue growth and discussed key product and pipeline developments, keeping attention on the durability of its retina franchise transition (EYLEA to EYLEA HD) and a broad set of clinical/regulatory milestones. Recent FDA milestones have also reinforced confidence in pipeline optionality, including the FDA approval of Otarmeni (lunsotogene parvec-cwha) for genetic hearing loss and the company’s plan to provide it free in the U.S. (investor.regeneron.com)
3) What to watch next
Near-term debate remains centered on the pace of EYLEA HD adoption versus base EYLEA declines and the timing/impact of upcoming competitive dynamics, while investors also track incremental regulatory decisions and key trial readouts across immunology, oncology, and rare disease programs. With the new $3 billion repurchase authorization in place, attention is also on the cadence of buybacks and whether management steps up purchases during periods of volatility. (sec.gov)